Frontage Labs, a US-China CRO, Acquires Concord Biosciences
publication date: Apr 6, 2018
Frontage Laboratories, a Pennsylvania-Shanghai pre-clinical CRO, acquired Concord Biosciences of Cleveland, Ohio for an undisclosed price. Concord, also a pre-clinical CRO, offers expertise in pharmaceuticals, agricultural, chemical and animal health. Frontage said the acquisition will allow it to offer a complete set of services to pharma clients, while adding agricultural products to its offerings. In 2014, Hangzhou Tigermed Consulting, a clinical-stage CRO, paid $50 million for a 70% equity interest in Frontage. More details....
Stock Symbol: (SHZ: 300347)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.